May 30, 2009
THE US Government has placed a $US180 million ($A232 million) order with CSL for vaccine antigen to swine flu as part of its preparations to combat a flu pandemic.
CSL said on Friday that the vaccine antigen for A(H1N1) influenza would be manufactured in Victoria.
The contract has been signed with a CSL subsidiary, CSL Biotherapies.
The vaccine will be manufactured at CSL's plant in Parkville, and will be tested in clinical trials funded by the United States Department of Health and Human Services.
CSL said the contract also provided the US Government with the opportunity to use CSL's antigen filling and finishing capability at the company's manufacturing plants in Kankakee, Illinois, in the US, and in Marburg, in Germany.
"CSL will maintain its commitment to supply seasonal influenza vaccines to Australia, the US and other markets," CSL said in a statement on Friday, including the swine flu vaccine.
"CSL's partnership with HHS (the US federal department) to address the serious threat to public health that the A(H1N1) virus represents, is confirmation that we are a leader in the global influenza vaccines market," CSL chief executive Brian McNamee said.
CSL said the $US180 million order was an initial amount.